These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1999686)

  • 41. On design considerations and randomization-based inference for community intervention trials.
    Gail MH; Mark SD; Carroll RJ; Green SB; Pee D
    Stat Med; 1996 Jun; 15(11):1069-92. PubMed ID: 8804140
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term effect of beta-blockade with timolol on maximal work capacity following myocardial infarction.
    Rønnevik PK; Gundersen T; Abrahamsen AM
    Eur Heart J; 1983 Nov; 4(11):773-80. PubMed ID: 6360689
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Power comparisons for group sequential tests with nonparametric statistics in case of nonproportional hazards.
    Demirhan H; Demirhan YP; Bacanli S
    J Biopharm Stat; 2013 Mar; 23(2):447-60. PubMed ID: 23437950
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Beta-blockade with timolol after myocardial infarction (author's transl)].
    Meister W
    MMW Munch Med Wochenschr; 1981 Sep; 123(38):1403-6. PubMed ID: 6793858
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials.
    Tamura RN; Huang X
    Clin Trials; 2007; 4(4):309-17. PubMed ID: 17848492
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
    Chen YH; Li C; Lan KK
    Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparing the fixed combination dorzolamide-timolol (Cosopt) to concomitant administration of 2% dorzolamide (Trusopt) and 0.5% timolol -- a randomized controlled trial and a replacement study.
    Francis BA; Du LT; Berke S; Ehrenhaus M; Minckler DS;
    J Clin Pharm Ther; 2004 Aug; 29(4):375-80. PubMed ID: 15271105
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Timolol-related reduction in mortality and reinfarction in diabetic patients surviving acute myocardial infarction.
    Gundersen T; Kjekshus J
    Horm Metab Res Suppl; 1985; 15():58-60. PubMed ID: 3908282
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Timolol after myocardial infarction: an answer or a new set of questions?
    Mitchell JR
    Br Med J (Clin Res Ed); 1981 May; 282(6276):1565-70. PubMed ID: 6113020
    [No Abstract]   [Full Text] [Related]  

  • 50. Flexible two-stage design with sample size reassessment for survival trials.
    Desseaux K; Porcher R
    Stat Med; 2007 Nov; 26(27):5002-13. PubMed ID: 17577242
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficient group sequential designs when there are several effect sizes under consideration.
    Jennison C; Turnbull BW
    Stat Med; 2006 Mar; 25(6):917-32. PubMed ID: 16220524
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design and analysis of group sequential logrank tests in maximum duration versus information trials.
    Kim K; Boucher H; Tsiatis AA
    Biometrics; 1995 Sep; 51(3):988-1000. PubMed ID: 7548714
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Approximating the power of Wilcoxon's rank-sum test against shift alternatives.
    Troendle JF
    Stat Med; 1999 Oct; 18(20):2763-73. PubMed ID: 10521865
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Beneficial effects of timolol on infarct size and late ventricular tachycardia in patients with acute myocardial infarction.
    Roqué F; Amuchastegui LM; Lopez Morillos MA; Mon GA; Girotti AL; Drajer S; Fortunato M; Moreyra E; Tuero P; Solchaga JC
    Circulation; 1987 Sep; 76(3):610-7. PubMed ID: 3304706
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The appropriateness of the Wilcoxon test in ordinal data.
    Hilton JF
    Stat Med; 1996 Mar; 15(6):631-45. PubMed ID: 8731005
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The importance of pre- and postinfarction angina on timolol-related reduction in mortality and reinfarction.
    Gundersen T; Kjekshus J
    Clin Cardiol; 1985 Feb; 8(2):87-92. PubMed ID: 3882290
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A rank-based sample size method for multiple outcomes in clinical trials.
    Huang P; Woolson RF; O'Brien PC
    Stat Med; 2008 Jul; 27(16):3084-104. PubMed ID: 18189338
    [TBL] [Abstract][Full Text] [Related]  

  • 59. On efficient two-stage adaptive designs for clinical trials with sample size adjustment.
    Liu Q; Li G; Anderson KM; Lim P
    J Biopharm Stat; 2012; 22(4):617-40. PubMed ID: 22651105
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Group-sequential three-arm noninferiority clinical trial designs.
    Ochiai T; Hamasaki T; Evans SR; Asakura K; Ohno Y
    J Biopharm Stat; 2017; 27(1):1-24. PubMed ID: 26892481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.